Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline

References

1. 1.↵
   2. Sevigny J,
   3. Chiao P,
   4. Bussière T, et al

   . The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016;537:50–56 doi:10.1038/nature19323 pmid:27582220

   CrossRefPubMed
2. 2.↵
   2. Kemppainen NM,
   3. Aalto S,
   4. Wilson IA, et al

   . PET amyloid ligand [11C] PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603–06 doi:10.1212/01.wnl.0000260969.94695.56 pmid:17485647

   Abstract/FREE Full Text
3. 3.↵
   2. Archer HA,
   3. Edison P,
   4. Brooks DJ, et al

   . Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145–47 doi:10.1002/ana.20889 pmid:16802294

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Tosun D,
   3. Schuff N,
   4. Mathis CA, et al

   ; Alzheimer's Disease Neuroimaging Initiative. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain 2011;134:1077–88 doi:10.1093/brain/awr044 pmid:21429865

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Oh H,
   3. Madison C,
   4. Villeneuve S, et al

   . Association of gray matter atrophy with age, β-amyloid, and cognition in aging. Cereb Cortex 2014;24:1609–18 doi:10.1093/cercor/bht017 pmid:23389995

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Storandt M,
   3. Mintun MA,
   4. Head D, et al

   . Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476–81 pmid:20008651

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Chételat G,
   3. Villemagne VL,
   4. Pike KE, et al

   ; Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010;133:3349–58 doi:10.1093/brain/awq187 pmid:20739349

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Jack CR Jr.,
   3. Lowe VJ,
   4. Weigand SD, et al

   ; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355–65 doi:10.1093/brain/awp062 pmid:19339253

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Insel PS,
   3. Mattsson N,
   4. Donohue MC, et al

   . The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimers Dement 2015;11:1171–79 doi:10.1016/j.jalz.2014.11.002 pmid:25499535

   CrossRefPubMed
10. 10.↵
    2. Kivipelto M,
    3. Ngandu T,
    4. Laatikainen T, et al

    . Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735–41 doi:10.1016/S1474-4422(06)70537-3 pmid:16914401

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Kivipelto M,
    3. Solomon A,
    4. Ahtiluoto S, et al

    . The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement 2013;9:657–65 doi:10.1016/j.jalz.2012.09.012 pmid:23332672

    CrossRefPubMed
12. 12.↵
    2. Ngandu T,
    3. Lehtisalo J,
    4. Solomon A, et al

    . A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255–63 doi:10.1016/S0140-6736(15)60461-5 pmid:25771249

    CrossRefPubMed
13. 13.↵
    2. Ngandu T,
    3. Lehtisalo J,
    4. Levälahti E, et al

    . Recruitment and baseline characteristics of participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)-a randomized controlled lifestyle trial. Int J Environ Res Public Health 2014;11:9345–60 doi:10.3390/ijerph110909345 pmid:25211775

    CrossRefPubMed
14. 14.↵
    2. Harrison J,
    3. Minassian SL,
    4. Jenkins L, et al

    . A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64:1323–29 doi:10.1001/archneur.64.9.1323 pmid:17846273

    CrossRefPubMedWeb of Science
15. 15.↵
    2. De la Vega FM,
    3. Lazaruk KD,
    4. Rhodes MD, et al

    . Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutat Res 2005;573:111–35 doi:10.1016/j.mrfmmm.2005.01.008 pmid:15829242

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Snellman A,
    3. Rokka J,
    4. López-Picón FR, et al

    . Applicability of [(11)C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiol Aging 2017;57:84–94 doi:10.1016/j.neurobiolaging.2017.05.008 pmid:28605642

    CrossRefPubMed
17. 17.↵
    2. Schulz V,
    3. Torres-Espallardo I,
    4. Renisch S, et al

    . Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging 2011;38:138–52 doi:10.1007/s00259-010-1603-1 pmid:20922522

    CrossRefPubMed
18. 18.↵
    2. Fischl B,
    3. Salat DH,
    4. Busa E, et al

    . Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–55 doi:10.1016/S0896-6273(02)00569-X pmid:11832223

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Ashburner J,
    3. Friston KJ

    . Unified segmentation. Neuroimage 2005;26:839–51 doi:10.1016/j.neuroimage.2005.02.018 pmid:15955494

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Hayasaka S,
    3. Phan KL,
    4. Liberzon I, et al

    . Nonstationary cluster-size inference with random field and permutation methods. Neuroimage 2004;22:676–87 doi:10.1016/j.neuroimage.2004.01.041 pmid:15193596

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Fazekas F,
    3. Chawluk JB,
    4. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Jack CR Jr.,
    3. Lowe VJ,
    4. Senjem ML, et al

    . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665–80 doi:10.1093/brain/awm336 pmid:18263627

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Mormino EC,
    3. Kluth JT,
    4. Madison CM, et al

    ; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310–23 doi:10.1093/brain/awn320 pmid:19042931

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Bourgeat P,
    3. Chételat G,
    4. Villemagne VL, et al

    ; AIBL Research Group. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010;74:121–27 doi:10.1212/WNL.0b013e3181c918b5 pmid:20065247

    Abstract/FREE Full Text
25. 25.↵
    2. Chételat G,
    3. Villemagne VL,
    4. Bourgeat P, et al

    ; Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67:317–24 doi:10.1002/ana.21955 pmid:20373343

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Mormino EC,
    3. Betensky RA,
    4. Hedden T, et al

    . Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014;71:1379–85 doi:10.1001/jamaneurol.2014.2031 pmid:25222039

    CrossRefPubMed
27. 27.↵
    2. Dickerson BC,
    3. Bakkour A,
    4. Salat DH, et al

    . The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009;19:497–510 doi:10.1093/cercor/bhn113 pmid:18632739

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Lerch JP,
    3. Pruessner JC,
    4. Zijdenbos A, et al

    . Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex 2005;15:995–1001 doi:10.1093/cercor/bhh200 pmid:15537673

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Mattsson N,
    3. Insel PS,
    4. Nosheny R, et al

    . Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol 2014;71:725–34 doi:10.1001/jamaneurol.2014.446 pmid:24781145

    CrossRefPubMed
30. 30.↵
    2. Galasko D,
    3. Chang L,
    4. Motter R, et al

    . High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937–45 doi:10.1001/archneur.55.7.937 pmid:9678311

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Honea RA,
    3. Vidoni E,
    4. Harsha A, et al

    . Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis 2009;18:553–64 doi:10.3233/JAD-2009-1163 pmid:19584447

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Liu Y,
    3. Paajanen T,
    4. Westman E, et al

    ; AddNeuroMed Consortium. Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis 2010;21:947–66 doi:10.3233/JAD-2010-100201 pmid:20693633

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Becker JA,
    3. Hedden T,
    4. Carmasin J, et al

    . Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032–42 doi:10.1002/ana.22333 pmid:21437929

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Falahati F,
    3. Ferreira D,
    4. Muehlboeck JS, et al

    . Monitoring disease progression in mild cognitive impairment: associations between atrophy patterns, cognition, APOE and amyloid. Neuroimage Clin 2017;16:418–28 doi:10.1016/j.nicl.2017.08.014 pmid:28879083

    CrossRefPubMed
35. 35.↵
    2. Chételat G,
    3. Fouquet M

    . Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers. Rev Neurol (Paris) 2013;169:729–36 doi:10.1016/j.neurol.2013.07.025 pmid:24016463

    CrossRefPubMed